American Tungsten & Antimony Ltd
ATALFDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How ATALF's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ferric Carboxymaltose (FCM) | Phase 2 | Restless Legs Syndrome (RLS) | - | - |
Frequently asked questions
What is in American Tungsten & Antimony Ltd's drug pipeline?→
CatalystAlert tracks 1 drug candidate in American Tungsten & Antimony Ltd's (ATALF) pipeline across Phase 2. Its lead program is Ferric Carboxymaltose (FCM) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is American Tungsten & Antimony Ltd's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for American Tungsten & Antimony Ltd (ATALF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ATALF biotech catalysts?→
Add ATALF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow American Tungsten & Antimony Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.